Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”
Dmitry S Karpov, Anastasiia O Sosnovtseva, Svetlana V Pylina, Asya N Bastrich, Darya A Petrova, Maxim A Kovalev, Anastasija I Shuvalova, Anna K Eremkina, Natalia G Mokrysheva, Hee-Jae Cha · 2023
Read Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse” by Dmitry S Karpov, Anastasiia O Sosnovtseva, Svetlana V Pylina, Asya N Bastrich, Darya A Petrova, Maxim A Kovalev, Anastasija I Shuvalova, Anna K Eremkina, Natalia G Mokrysheva, Hee-Jae Cha (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10743607.txt.
Description
Dmitry S Karpov and co-authors review gene-edited cell therapy for type 1 diabetes in a 2023 paper. In this disease, the immune system kills the cells in the pancreas that make insulin, and no drug yet stops that process. Insulin shots save lives but are costly and can cause harm over time, which drives the search for a cell-based fix.
Editing tools such as CRISPR could shape lab-grown replacement cells, but the tools can cut in wrong places and edits can misfire. The authors warn that a badly made cell product could act like a Trojan horse, harming the patient it was meant to help. They weigh new plans for building such cells and argue that careful design is the price of safety.
Catalog record
| CREATOR | Dmitry S Karpov, Anastasiia O Sosnovtseva, Svetlana V Pylina, Asya N Bastrich, Darya A Petrova, Maxim A Kovalev, Anastasija I Shuvalova, Anna K Eremkina, Natalia G Mokrysheva, Hee-Jae Cha |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |